Pfizer to buy Vicuron Pharmaceuticals for $1.9 billion

Share this article:
Pfizer has agreed to acquire biopharmaceutical company Vicuron Pharmaceuticals for $1.9 billion in a move to expand its offerings of anti-infective products.
Vicuron, based in King of Prussia, Pa., has two products currently under new drug application review at the FDA.
The products are anidulafungin for fungal infections and dalbavancin for skin and soft tissue infections. Both have shown positive results in late-stage studies, according to published reports.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.